CYTX Cytori Therapeutics Inc

1.06
0  -4%
Previous Close 1.10
Open 1.10
Price To book 2.17
Market Cap 24.98M
Shares 23,568,000
Volume 508,507
Short Ratio 1.99
Av. Daily Volume 695,586

SEC filingsSee all SEC filings

  1. EFFECT - Notice of Effectiveness 17782371
  2. CT ORDER - Confidential treatment order 17777232
  3. 8-K - Current report 17758595
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17758576
  5. DEF 14A - Other definitive proxy statements 17754227

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced mid-January 2016 that first patients have been enrolled
Cytori Cell Therapy
Crohn’s Disease
Pivotal trial initiated August 2015. Enrolment completed June 2016. Data are due 3Q 2017.
ECCS-50
Scleroderma
Phase 2 interim data released February 2016 noted that the pre-specified primary endpoint did not obtain statistical significance. Full data due 3Q 2016
ECCO-50 cellular therapeutic
Osteoarthritis of the knee
Enrolling
Cell Enriched Adipose
Early stage female and male pattern hair loss

Latest News

  1. Cytori Therapeutics Stock Sliding on Offering Price Discount
  2. Cytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount
  3. Cytori Announces Pricing of $9.5M Public Offering of Common Stock
  4. Today's Research Reports on Biotech Stocks to Watch: Cytori Therapeutics and Geron
  5. Cytori Announces Proposed Public Offering of Common Stock
  6. Cytori Get FDA Approval for Clinical Burn Trial
  7. ETFs with exposure to Cytori Therapeutics, Inc. : April 10, 2017
  8. Cytori Rises on Crucial FDA Approval
  9. Cytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract
  10. Cytori Appoints Gregg Lapointe to Board of Directors
  11. ETFs with exposure to Cytori Therapeutics, Inc. : March 30, 2017
  12. Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017
  13. Cytori reports 4Q loss
  14. Cytori Reports Fourth Quarter and Full Year 2016 Business and Financial Results
  15. Cytori to Webcast Fourth Quarter Financial Results on March 23rd
  16. Cytori Completes Acquisition of Azaya Therapeutics Assets, Initiates Nanomedicine Program
  17. Cytori Provides Latest Corporate Update at the 2nd Annual Disruptive Growth & Healthcare Conference
  18. Cytori Wins Small Business Status, Stock Spikes
  19. Cytori Receives U.S. Small Business Designation - Substantially Reduces 2017 FDA Filing Fees
  20. Cytori To Buy Cancer Drug Group Azaya for $170M

SEC Filings

  1. EFFECT - Notice of Effectiveness 17782371
  2. CT ORDER - Confidential treatment order 17777232
  3. 8-K - Current report 17758595
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17758576
  5. DEF 14A - Other definitive proxy statements 17754227
  6. 424B5 - Prospectus (Rule 424(b)(5)) 17753429
  7. 8-K - Current report 17751623
  8. 8-K - Current report 17743495
  9. 424B3 - Prospectus (Rule 424(b)(3)) 17730917
  10. EFFECT - Notice of Effectiveness 17727810